TrialCell research2021

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.

Yi-Zhou Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.